By Sheeba M. | May 6, 2026

Cannabis MSOs Post Record Profitability as Federal Headwinds Ease

TL;DR: Multi-state operators report Q1 2026 EBITDA margins above 25% for the first time, signaling a pivotal shift toward sustainable profitability as banking reform gains momentum.

The cannabis sector is experiencing a watershed moment. Major multi-state operators (MSOs) including Curaleaf, Trulieve, and Verano announced Q1 2026 results this week showing EBITDA margins climbing above 25%—a level previously thought impossible under Section 280E constraints.

This breakthrough reflects two converging forces: disciplined operational scaling and legislative momentum toward federal banking reform. The SAFE Banking Act’s path toward a floor vote in June has emboldened institutional capital, creating conditions for the first truly profitable cohort of cannabis operators.

The Unit Economics Inflection

The critical metric isn’t revenue growth—it’s **normalized EBITDA** after 280E adjustments. Curaleaf‘s fiscal Q1 reported normalized EBITDA of $187M on $583M revenue (32% margin), up from 28% in the prior year. This is sustainable profitability, not accounting tricks.

For context: Two years ago, most MSOs operated at 12-15% margins while burning cash on regulatory compliance. The sector has fundamentally shifted. Consolidation of underperforming markets, exit from unprofitable states, and vendor leverage renegotiation have created a leaner operating model.

The Banking Question

SAFE Banking passage remains the catalyst the market is pricing in, but it’s no longer binary. Trulieve‘s investor call emphasized that even **without SAFE**, they achieve positive free cash flow by Q4 2026. That’s a game-changer—it means growth capital is no longer contingent on legislation.

If SAFE passes (65% probability by Q3), expect a 15-25% sector-wide revaluation as institutional capital reallocates to cannabis from illiquid consumer staples.

Stocks to Watch

Track the majors on the Weedstock Real-Time Tracker: Curaleaf, Trulieve, Verano, and emerging smaller-cap plays like Cresco Labs. Margin expansion is the real story—follow EBITDA beats, not just revenue.

Sources

Leave a Reply

📅 Yesterday's News & Older Articles →